EUVIMEDEUVIMED entdecken
Crossref

Targeting eIF5A2 hypusination with bikinin sensitizes hepatocellular carcinoma to lenvatinib by suppressing TFEB-mediated autophagy

Shuqian Wang, Qingyun Zhou, Qiaomei Lin, Shufen Zhang, Ying Cai, Fangnan Wu, Fangyuan Kuang, Lianghui Wang, Shangzhi Xie, Jiahua Lan, Li Zheng, Guodong Xu und 3 weitere

Human Cell · 18.07.2026 · 39 (8)

DOI: 10.1007/s13577-026-01426-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Cell, online erschienen am 18.07.2026. Verfasst von Shuqian Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, Zhejiang, China. Hauptthemen laut MEDLINE: Phenylurea Compounds, Quinolines, Carcinoma, Hepatocellular, Autophagy. Die Arbeit nennt 49 Literaturangaben. Gefördert von: Natural Science Foundation of Zhejiang Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) frequently develops resistance to lenvatinib, a multikinase inhibitor, necessitating the development of novel therapeutic strategies. Here, we identify bikinin as a potent eIF5A2 inhibitor through structure-based virtual screening (> 100,000 compounds) and demonstrate its synergistic effect with lenvatinib in HCC cells. Mechanistically, bikinin suppresses deoxyhypusine synthase (DHS)-mediated hypusination of eIF5A2, thereby downregulating the expression of transcription factor EB (TFEB). Furthermore, while DHS knockdown enhanced the sensitivity of HCC cells to lenvatinib, the addition of bikinin treatment provided no further significant sensitization. We also observed that the combination of bikinin and lenvatinib significantly promoted apoptosis and suppressed proliferation in HCC cells. Although TFEB overexpression conferred resistance to lenvatinib and activated autophagy, these effects were reversed by co-treatment with bikinin, which restored lenvatinib sensitivity and inhibited autophagic flux. Bikinin disrupts TFEB-driven autophagy, as evidenced by reduced LC3-II conversion, p62 accumulation, and decreased autophagosome formation. In in vivo experiments, the combination therapy with lenvatinib and bikinin achieved marked tumor regression, accompanied by suppressed Ki-67 expression and elevated TUNEL positivity. Finally, RNA-seq data identified TFEB downregulation as a critical mediator of this therapeutic sensitization. Our work unveils a novel therapeutic axis wherein targeting eIF5A2 hypusination disrupts TFEB-dependent autophagy to overcome lenvatinib resistance in HCC cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phenylurea CompoundsQuinolinesCarcinoma, HepatocellularAutophagyLiver NeoplasmsRNA-Binding ProteinsPeptide Initiation FactorsBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsAntineoplastic AgentsHumansEukaryotic Translation Initiation Factor 5ADrug SynergismAnimalsDrug Resistance, NeoplasmApoptosisCell Line, TumorGene ExpressionCell ProliferationOxidoreductases Acting on CH-NH Group DonorsLysine

Stichwörter der Autor:innen

AutophagyHepatocellular carcinomaHypusinationLenvatinibeIF5A2

Substanzen

Phenylurea CompoundsQuinolinesRNA-Binding ProteinslenvatinibEukaryotic Translation Initiation Factor 5APeptide Initiation FactorsBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsAntineoplastic Agentshypusinedeoxyhypusine synthase

Autor:innen und Institutionen

  • Department of Breast Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, Zhejiang, China.
  • Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
  • Department of General Surgery, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, Lishui, 323000, Zhejiang, China.
  • Cancer Institute of Integrated Traditional Chinese and Western Medicine, Key Laboratory of Cancer Prevention and Therapy Combining Traditional Chinese and Western Medicine of Zhejiang Province, Zhejiang Academy of Tradi…
  • Department of General Surgery, Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, Lishui, 323000, Zhejiang, China.
  • Department of Thoracic Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang, China.

Förderung

  • Natural Science Foundation of Zhejiang Province
  • National Natural Science Foundation of China

Zitieren

APA

Wang, S., Zhou, Q., Lin, Q., Zhang, S., Cai, Y., Wu, F., Kuang, F., Wang, L., Xie, S., Lan, J., Zheng, L., Xu, G., Shao, C., Chen, W., & Tu, C. (2026). Targeting eIF5A2 hypusination with bikinin sensitizes hepatocellular carcinoma to lenvatinib by suppressing TFEB-mediated autophagy. Human Cell, 39(8). https://doi.org/10.1007/s13577-026-01426-9

Vancouver

Wang S, Zhou Q, Lin Q, Zhang S, Cai Y, Wu F, et al. Targeting eIF5A2 hypusination with bikinin sensitizes hepatocellular carcinoma to lenvatinib by suppressing TFEB-mediated autophagy. Human Cell. 2026;39(8). doi:10.1007/s13577-026-01426-9

BibTeX
@article{Wang2026,
  author = {Wang, Shuqian and Zhou, Qingyun and Lin, Qiaomei and Zhang, Shufen and Cai, Ying and Wu, Fangnan and Kuang, Fangyuan and Wang, Lianghui and Xie, Shangzhi and Lan, Jiahua and Zheng, Li and Xu, Guodong and Shao, Chuxiao and Chen, Wei and Tu, Chaoyong},
  title = {Targeting eIF5A2 hypusination with bikinin sensitizes hepatocellular carcinoma to lenvatinib by suppressing TFEB-mediated autophagy},
  journal = {Human Cell},
  year = {2026},
  volume = {39},
  number = {8},
  doi = {10.1007/s13577-026-01426-9}
}
Kostenlos starten →